The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

One of these suggested stocks features a dividend yield topping 10%.

Shares of global pharmaceutical company Pfizer (NYSE:PFE) fell 2.5% in the morning session after the company cut its stake in its pandemic partner BioNTech by more than half, a move that overshadowed ...

Pfizer will relinquish its stake in ViiV Healthcare in a deal valued at just over $2.1 billion that ramps up Shionogi's ...

Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.

The pharmaceutical company updated its sales guidance for 2025, saying it now expects $62 billion in revenue for the year Pfizer revised its revenue expectations for 2025 and detailed its outlook for ...

Pfizer last month completed an acquisition of biotech firm Metsera, deepening its portfolio of products in the fast-growing market for weight loss drugs - Copyright ...

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, with more money and help from the Trump administration Pfizer won its fight to ...

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...